Skip to main content
Top
Published in: Virology Journal 1/2008

Open Access 01-12-2008 | Short report

HIV-2 neutralization by intact V3-specific Fab fragments

Authors: Samer Sourial, Charlotta Nilsson

Published in: Virology Journal | Issue 1/2008

Login to get access

Abstract

The V3 region of both HIV-1 gp120 and HIV-2 gp125 surface glycoprotein has been described as a target for neutralizing antibodies. In this study a conformation-sensitive (3C4) and a linear site-specific (7C8) anti-HIV-2 V3 monoclonal antibody (mAb) were characterized. The neutralization capacity of the purified mAbs and their respective papain-generated Fab fragments was analyzed. The Fabs were further characterized by sequence analysis. Our results demonstrate that neither purified mAbs were capable of neutralizing HIV-2, while intact Fab fragments from both mAbs blocked in vitro infection of HIV-2 isolates. Moreover, the conformation sensitive 3C4 Fab neutralized both subtype A and B HIV-2 isolates and SIVsm. Sequence analysis of the hypervariable regions of 3C4 Fab and 7C8 Fab revealed that the third CDR of the heavy chain (CDRH3) of the antibodies was not as long as many of the previously characterized neutralizing antibodies. Our findings suggest that whole 7C8 and 3C4 mAbs are sterically hindered from neutralizing HIV-2, whereas the smaller size of Fab fragments enables access to the V3 region on the virion surface.
Appendix
Available only for authorised users
Literature
1.
go back to reference Huber M, Trkola A: Humoral immunity to HIV-1: neutralization and beyond. J Internal Med 2007, 262: 5-25. 10.1111/j.1365-2796.2007.01819.xCrossRefPubMed Huber M, Trkola A: Humoral immunity to HIV-1: neutralization and beyond. J Internal Med 2007, 262: 5-25. 10.1111/j.1365-2796.2007.01819.xCrossRefPubMed
2.
go back to reference Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Steigler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78: 13232-13252. 10.1128/JVI.78.23.13232-13252.2004PubMedCentralCrossRefPubMed Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Steigler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78: 13232-13252. 10.1128/JVI.78.23.13232-13252.2004PubMedCentralCrossRefPubMed
3.
go back to reference Conley AJ, Gorny MK, Kessler JA II, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, Zolla-Pazner S: Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994, 68: 6994-7000.PubMedCentralPubMed Conley AJ, Gorny MK, Kessler JA II, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, Zolla-Pazner S: Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994, 68: 6994-7000.PubMedCentralPubMed
4.
go back to reference Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK: The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses 2004, 20: 1254-1258. 10.1089/aid.2004.20.1254CrossRefPubMed Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK: The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses 2004, 20: 1254-1258. 10.1089/aid.2004.20.1254CrossRefPubMed
5.
go back to reference Gorny MK, Revesz K, Williams C, Volsky B, Lauder MK, Anyanywe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S: The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 2004, 78: 2394-2404. 10.1128/JVI.78.5.2394-2404.2004PubMedCentralCrossRefPubMed Gorny MK, Revesz K, Williams C, Volsky B, Lauder MK, Anyanywe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S: The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 2004, 78: 2394-2404. 10.1128/JVI.78.5.2394-2404.2004PubMedCentralCrossRefPubMed
6.
go back to reference Krachmarov CP, Honnen WJ, Kayman SC, Gorney MK, Zolla-Pazner S, Pinter A: Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A and clade B strains of human immunodeficiency virus type 1. J Virol 2006, 80: 7127-7135. 10.1128/JVI.02619-05PubMedCentralCrossRefPubMed Krachmarov CP, Honnen WJ, Kayman SC, Gorney MK, Zolla-Pazner S, Pinter A: Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A and clade B strains of human immunodeficiency virus type 1. J Virol 2006, 80: 7127-7135. 10.1128/JVI.02619-05PubMedCentralCrossRefPubMed
7.
go back to reference Björling E, Broliden K, Bernardi D, Utter G, Thorstensson R, Chiodi F, Norrby E: Hyperimmune antisera against synthetic peptides representing the glycoprotein of human ummundeficiency virus type 2 can mediate neutralization and antibody-mediated cytotoxic activity. Proc Natl Acad Sci USA 1991, 88: 6082-6086. 10.1073/pnas.88.14.6082PubMedCentralCrossRefPubMed Björling E, Broliden K, Bernardi D, Utter G, Thorstensson R, Chiodi F, Norrby E: Hyperimmune antisera against synthetic peptides representing the glycoprotein of human ummundeficiency virus type 2 can mediate neutralization and antibody-mediated cytotoxic activity. Proc Natl Acad Sci USA 1991, 88: 6082-6086. 10.1073/pnas.88.14.6082PubMedCentralCrossRefPubMed
8.
go back to reference Matsushita S, Matsumi S, Yoshimura K, Morikita T, Murakami T, Takatsuki K: Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120. J Virol 1995, 69: 3333-3340.PubMedCentralPubMed Matsushita S, Matsumi S, Yoshimura K, Morikita T, Murakami T, Takatsuki K: Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120. J Virol 1995, 69: 3333-3340.PubMedCentralPubMed
9.
go back to reference Björling E, Chiodi F, Utter G, Norrby E: Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2. J Immunol 1994, 152: 1952-1959.PubMed Björling E, Chiodi F, Utter G, Norrby E: Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2. J Immunol 1994, 152: 1952-1959.PubMed
10.
go back to reference McKnight A, Shotton C, Cordell J, Jones I, Simmons G, Clapham PR: Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol 1996, 70: 4598-4606.PubMedCentralPubMed McKnight A, Shotton C, Cordell J, Jones I, Simmons G, Clapham PR: Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol 1996, 70: 4598-4606.PubMedCentralPubMed
11.
go back to reference Mörner A, Björndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyö EM, Björling E: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999, 73: 2343-2349.PubMedCentralPubMed Mörner A, Björndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyö EM, Björling E: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999, 73: 2343-2349.PubMedCentralPubMed
12.
go back to reference McKnight A, Dittmar MT, Moniz-Periera J, Ariyoshi K, Reeves JD, Hibbitts S, Whitby D, Aarons E, Proudfoot AE, Whittle H, Clapham PR: A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol 1998, 72: 4065-4071.PubMedCentralPubMed McKnight A, Dittmar MT, Moniz-Periera J, Ariyoshi K, Reeves JD, Hibbitts S, Whitby D, Aarons E, Proudfoot AE, Whittle H, Clapham PR: A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol 1998, 72: 4065-4071.PubMedCentralPubMed
13.
go back to reference Sourial S, Nilsson C, Wärnmark A, Achour A, Harris RA: Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125. Curr HIV Res 2006, 4: 229-237. 10.2174/157016206776055066CrossRefPubMed Sourial S, Nilsson C, Wärnmark A, Achour A, Harris RA: Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125. Curr HIV Res 2006, 4: 229-237. 10.2174/157016206776055066CrossRefPubMed
14.
go back to reference Lizeng Q, Skott P, Sourial S, Nilsson C, Andersson S, Ehnlund M, Taveira N, Björling E: Serum immunolglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 2003, 308: 225-232. 10.1016/S0042-6822(02)00088-0CrossRefPubMed Lizeng Q, Skott P, Sourial S, Nilsson C, Andersson S, Ehnlund M, Taveira N, Björling E: Serum immunolglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 2003, 308: 225-232. 10.1016/S0042-6822(02)00088-0CrossRefPubMed
15.
go back to reference Thorstensson R, Walther L, Putkonen P, Albert J, Biberfeld G: A capture enzyme immunoassay for detection of HIV-2/SIV antigen. J Acquir Immune Defic Syndr 1991,4(4):374-379.PubMed Thorstensson R, Walther L, Putkonen P, Albert J, Biberfeld G: A capture enzyme immunoassay for detection of HIV-2/SIV antigen. J Acquir Immune Defic Syndr 1991,4(4):374-379.PubMed
16.
go back to reference Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR: Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003, 77: 10557-10565. 10.1128/JVI.77.19.10557-10565.2003PubMedCentralCrossRefPubMed Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR: Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003, 77: 10557-10565. 10.1128/JVI.77.19.10557-10565.2003PubMedCentralCrossRefPubMed
17.
go back to reference Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994, 68: 4821-4828.PubMedCentralPubMed Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994, 68: 4821-4828.PubMedCentralPubMed
18.
go back to reference Parham P: Preparation and purification of active fragments from mouse monoclonal antibodies. In Cellular Immunology. Volume 1. 4th edition. Edited by: Weir DM. California: Blackwell Scientific Publications; 1986. Parham P: Preparation and purification of active fragments from mouse monoclonal antibodies. In Cellular Immunology. Volume 1. 4th edition. Edited by: Weir DM. California: Blackwell Scientific Publications; 1986.
19.
go back to reference Ornatowska M, Glasel JA: Direct production of Fv-fragments from a family of monoclonal IgGs papain digestion. Mol Immunol 1991, 28: 383-391. 10.1016/0161-5890(91)90151-9CrossRefPubMed Ornatowska M, Glasel JA: Direct production of Fv-fragments from a family of monoclonal IgGs papain digestion. Mol Immunol 1991, 28: 383-391. 10.1016/0161-5890(91)90151-9CrossRefPubMed
20.
go back to reference McInerney TL, McLain L, Armstrong SJ, Dimmock NJ: A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 1997, 233: 313-26. 10.1006/viro.1997.8547CrossRefPubMed McInerney TL, McLain L, Armstrong SJ, Dimmock NJ: A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 1997, 233: 313-26. 10.1006/viro.1997.8547CrossRefPubMed
21.
go back to reference Edwards MJ, Dimmock NJ: Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 2000, 278: 423-435. 10.1006/viro.2000.0631CrossRefPubMed Edwards MJ, Dimmock NJ: Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 2000, 278: 423-435. 10.1006/viro.2000.0631CrossRefPubMed
22.
go back to reference Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF: Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 2003, 325: 325-335. 10.1016/S0022-2836(02)01232-9CrossRefPubMed Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF: Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 2003, 325: 325-335. 10.1016/S0022-2836(02)01232-9CrossRefPubMed
23.
go back to reference Wu TT, Johnson G, Kabat EA: Length distribution of CDRH3 in antibodies. Proteins 1993, 16: 1-7. 10.1002/prot.340160102CrossRefPubMed Wu TT, Johnson G, Kabat EA: Length distribution of CDRH3 in antibodies. Proteins 1993, 16: 1-7. 10.1002/prot.340160102CrossRefPubMed
24.
go back to reference Johnson G, Wu TT: Preferred CDRH3 lengths for antibodies with defined specificities. Int Immunology 1998, 10: 1801-1805. 10.1093/intimm/10.12.1801CrossRef Johnson G, Wu TT: Preferred CDRH3 lengths for antibodies with defined specificities. Int Immunology 1998, 10: 1801-1805. 10.1093/intimm/10.12.1801CrossRef
25.
go back to reference Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393: 648-659. 10.1038/31405CrossRefPubMed Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393: 648-659. 10.1038/31405CrossRefPubMed
26.
go back to reference Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structures of HIV-1 gp120 envelope glycoprotein from lab-adapted and primary isolates. Structure 2000, 8: 1329-1339. 10.1016/S0969-2126(00)00547-5CrossRefPubMed Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structures of HIV-1 gp120 envelope glycoprotein from lab-adapted and primary isolates. Structure 2000, 8: 1329-1339. 10.1016/S0969-2126(00)00547-5CrossRefPubMed
27.
go back to reference Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA: Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001, 293: 1155-1159. 10.1126/science.1061692CrossRefPubMed Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA: Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001, 293: 1155-1159. 10.1126/science.1061692CrossRefPubMed
28.
go back to reference Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PW, Kunert R, Katinger H, Wilson IA, Burton DR: The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 2004, 78: 3155-3161. 10.1128/JVI.78.6.3155-3161.2004PubMedCentralCrossRefPubMed Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PW, Kunert R, Katinger H, Wilson IA, Burton DR: The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 2004, 78: 3155-3161. 10.1128/JVI.78.6.3155-3161.2004PubMedCentralCrossRefPubMed
29.
go back to reference Dharba R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, Burton DR, Dimitrov DS, Ji X: Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 2004, 43: 1410-1417. 10.1021/bi035323xCrossRef Dharba R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, Burton DR, Dimitrov DS, Ji X: Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 2004, 43: 1410-1417. 10.1021/bi035323xCrossRef
30.
go back to reference Vödrös D, Thorstensson R, Biberfeld G, Schols D, De Clercq E, Fenyo EM: Coreceptor usage of sequential isolates from cynomolgus monkeys experimentally infected with simian immunodeficiency virus (SIVsm). Virology 2001, 291: 12-21. 10.1006/viro.2001.1164CrossRefPubMed Vödrös D, Thorstensson R, Biberfeld G, Schols D, De Clercq E, Fenyo EM: Coreceptor usage of sequential isolates from cynomolgus monkeys experimentally infected with simian immunodeficiency virus (SIVsm). Virology 2001, 291: 12-21. 10.1006/viro.2001.1164CrossRefPubMed
Metadata
Title
HIV-2 neutralization by intact V3-specific Fab fragments
Authors
Samer Sourial
Charlotta Nilsson
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2008
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-5-96

Other articles of this Issue 1/2008

Virology Journal 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.